GO
Loading...

Court Upholds Ruling in Favor of Eli Lilly

A U.S. appeals court affirmed a 2005 ruling by a federal judge that upheld the validity of a disputed patent on Eli Lilly and Co.'s top-selling schizophrenia drug Zyprexa.

The U.S. Court of Appeals for the Federal Circuit said it had found no reversible error in the April 2005 ruling by U.S. District Court Judge Richard Young, which handed the company a major victory in its efforts to hold off generic competition.

The patent at issue in the case runs through April of 2011 and had been contested by Israel's Teva Pharmaceuticals and Indian drugmaker Dr. Reddy's Laboratories.

Representatives for Teva and Dr. Reddy's could not immediately reached for comment.

In 2005, Zyprexa made up 29 percent of Eli Lilly's $2.6 billion sales.

In the ruling issued on Tuesday, the appeals court rejected a series of arguments by the generic challengers aimed at overturning the earlier ruling.

The generic companies contended the Zyprexa patent was invalid because it was too similar to a previous patent held by Lilly, and that a form of the drug was in public use before Lilly received its patents.

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More

Don't Miss

U.S. Video

  • CNBC's Robert Frank reports Alibaba's Jack Ma plans to sell $1 billion or more worth of his shares in the company, and his total net worth is now $27 billion.

  • CNBC's Josh Lipton reports from Palo Alto, California, where hundreds of Apple fans lined up to buy the new iPhones. Tim Cook's CEO says he has both the iPhone 6 and 6 Plus.

  • Barry James of James Advantage Funds, thinks investors should let the froth die in Alibaba before getting in; and Michael Crofton, Philadelphia Trust Company CEO,